These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28739783)

  • 1. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.
    Ford SL; Sutton K; Lou Y; Zhang Z; Tenorio A; Trezza C; Patel P; Spreen W
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
    Ford SL; Lou Y; Lewis N; Kostapanos M; D'Amico R; Spreen W; Patel P
    Antivir Ther; 2019; 24(4):301-308. PubMed ID: 30896438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
    Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
    PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
    Landovitz RJ; Li S; Eron JJ; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Eshleman SH; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Cohen MS; McCauley M; Hendrix CW
    Lancet HIV; 2020 Jul; 7(7):e472-e481. PubMed ID: 32497491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants.
    Parasrampuria R; Ford SL; Lou Y; Fu C; Bakshi KK; Tenorio AR; Trezza C; Spreen WR; Patel P
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):674-681. PubMed ID: 30809978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir.
    Patel P; Ford SL; Lou Y; Bakshi K; Tenorio AR; Zhang Z; Pan R; Spreen W
    Clin Pharmacol Drug Dev; 2019 May; 8(4):443-448. PubMed ID: 30230694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls.
    Shaik JSB; Ford SL; Lou Y; Zhang Z; Bakshi KK; Tenorio AR; Trezza C; Spreen WR; Patel P
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):664-673. PubMed ID: 30811880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling.
    Rajoli RKR; Curley P; Chiong J; Back D; Flexner C; Owen A; Siccardi M
    J Infect Dis; 2019 May; 219(11):1735-1742. PubMed ID: 30566691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women.
    Trezza C; Ford SL; Gould E; Lou Y; Huang C; Ritter JM; Buchanan AM; Spreen W; Patel P
    Br J Clin Pharmacol; 2017 Jul; 83(7):1499-1505. PubMed ID: 28087972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
    Gaur AH; Capparelli EV; Calabrese K; Baltrusaitis K; Marzinke MA; McCoig C; Van Solingen-Ristea RM; Mathiba SR; Adeyeye A; Moye JH; Heckman B; Lowenthal ED; Ward S; Milligan R; Samson P; Best BM; Harrington CM; Ford SL; Huang J; Crauwels H; Vandermeulen K; Agwu AL; Smith-Anderson C; Camacho-Gonzalez A; Ounchanum P; Kneebone JL; Townley E; Bolton Moore C; ;
    Lancet HIV; 2024 Apr; 11(4):e211-e221. PubMed ID: 38538160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects.
    Lou Y; Buchanan AM; Chen S; Ford SL; Gould E; Margolis D; Spreen WR; Patel P
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):509-516. PubMed ID: 27162089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor.
    Cattaneo D; Gervasoni C
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):319-327. PubMed ID: 30387005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
    Han K; Wannamaker P; Lu H; Zhu B; Wang M; Paff M; Spreen WR; Ford SL
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205721. PubMed ID: 35129374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and pharmacology of long-acting cabotegravir.
    Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S
    Curr Opin HIV AIDS; 2015 Jul; 10(4):239-45. PubMed ID: 26049948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
    Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
    Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
    Shaik JS; Weld ED; Edick S; Fuchs E; Riddler S; Marzinke MA; D'Amico R; Bakshi K; Lou Y; Hendrix C; Han K; Ford SL; Margolis D; Spreen W; Patel P
    Br J Clin Pharmacol; 2022 Feb; 88(4):1667-1678. PubMed ID: 34240467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.